Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Laurie J Barten, Douglas R Allington, Kendra A Procacci & Michael P Rivey. (2010) New approaches in the management of multiple sclerosis. Drug Design, Development and Therapy 4, pages 343-366.
Read now
Read now
Articles from other publishers (13)
Brandon Tapasak, Luke Edelmayer & Michael D. Seidman. (2022) Endocannabinoid System and the Otolaryngologist. Otolaryngologic Clinics of North America 55:5, pages 1101-1110.
Crossref
Crossref
Rüdiger Birke, Stefanie Meister, Alexander Winkelmann, Burkhard Hinz & Udo I. Walther. (2022) Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis. Journal of Clinical Medicine 11:13, pages 3717.
Crossref
Crossref
Victor Longoria, Hannah Parcel, Bameelia Toma, Annu Minhas & Rana Zeine. (2022) Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. Biomedicines 10:3, pages 539.
Crossref
Crossref
Zaid H. Maayah & Jason R. B. Dyck. (2020) The pharmacological effects of inhaled cannabis on pain in patients with multiple sclerosis: risks versus rewards. Inflammation Research 69:11, pages 1073-1076.
Crossref
Crossref
Steven M. Bailey & Claire M. Rice. 2018. Progressive Multiple Sclerosis. Progressive Multiple Sclerosis
155
205
.
Sheng-Jia Shi, Mei-Ling Ding, Li-Juan Wang, Jie-Heng Wu, Dong-Hui Han, Guo-Xu Zheng, Zhang-Yan Guo, Wen-Jin Xi, Wei-Jun Qin, An-Gang Yang & Wei-Hong Wen. (2017) CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis. Oncotarget 8:52, pages 90028-90036.
Crossref
Crossref
Claire M. Rice & Alastair Wilkins. 2013. Progressive Multiple Sclerosis. Progressive Multiple Sclerosis
147
186
.
Erin L. Karschner, David M. Schwope, Eugene W. Schwilke, Robert S. Goodwin, Deanna L. Kelly, David A. Gorelick & Marilyn A. Huestis. (2012) Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug and Alcohol Dependence 125:3, pages 313-319.
Crossref
Crossref
Viktor Rempel, Nicole Volz, Sonja Hinz, Tadeusz Karcz, Irene Meliciani, Martin Nieger, Wolfgang Wenzel, Stefan Bräse & Christa E. Müller. (2012) 7-Alkyl-3-benzylcoumarins: A Versatile Scaffold for the Development of Potent and Selective Cannabinoid Receptor Agonists and Antagonists. Journal of Medicinal Chemistry 55:18, pages 7967-7977.
Crossref
Crossref
Zhi-Yin Lou, Chong-Bo Zhao & Bao-Guo Xiao. (2012) Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. Journal of Neuroscience Research 90:1, pages 84-95.
Crossref
Crossref
Analia Veitz-Keenan & Silvia Spivakovsky. (2011) Cannabis use and oral diseases. Evidence-Based Dentistry 12:2, pages 38-38.
Crossref
Crossref
Alexander G. Rabchevsky & Patrick H. Kitzman. (2011) Latest Approaches for the Treatment of Spasticity and Autonomic Dysreflexia in Chronic Spinal Cord Injury. Neurotherapeutics 8:2, pages 274-282.
Crossref
Crossref
Dennis A. NowakF. Binkofski, M. Dafotakis, C. Dohle, C. Eickhof, D. Ertelt, C. Grefkes, F. Hamzei, B. Hauptmann, S. Hesse, R. Horst, H. Hummelsheim, J. Liepert, D.A. Nowak, C. Müller, T. Platz, C.I.E. Renner, V. Urquizo, M.S. Vry, C. Werner & H. Woldag. 2011. Handfunktionsstörungen in der Neurologie. Handfunktionsstörungen in der Neurologie
191
301
.